Skip Navigation
Skip to contents

Epidemiol Health : Epidemiology and Health

OPEN ACCESS
SEARCH
Search
Advanced Search
mobile menu button

Search

Page Path
HOME > Search
1 "Aliabbas A. Husain"
Filter
Filter
Article category
Keywords
Publication year
Authors
Perspective
Controlling the drug-resistant tuberculosis epidemic in India: challenges and implications
Aliabbas A. Husain, Andreas Kupz, Rajpal S. Kashyap
Epidemiol Health. 2021;43:e2021022.   Published online April 7, 2021
DOI: https://doi.org/10.4178/epih.e2021022
  • 12,196 View
  • 425 Download
  • 3 Web of Science
  • 4 Crossref
AbstractAbstract AbstractSummary PDF
Abstract
India has a higher tuberculosis (TB) burden than any other country, accounting for an estimated one-fourth of the global burden. Drug-resistant tuberculosis (DR-TB) presents a major public health problem in India. Patients with DR-TB often require profound changes in their drug regimens, which are invariably linked to poor treatment adherence and sub-optimal treatment outcomes compared to drug-sensitive TB. The challenge of addressing DR-TB is critical for India, as India contributes over 27% of global DR-TB cases. In recent decades, India has been proactive in its battle against TB, even implementing a revised National Strategic Plan to eliminate TB by 2025. However, to achieve this ambitious goal, the country will need to take a multifaceted approach with respect to its management of DR-TB. Despite concerted efforts made by the National TB Elimination Program, India faces substantial challenges with regard to DR-TB care, especially in peripheral and resource-limited endemic zones. This article describes some of the major challenges associated with mitigating the growing DR-TB epidemic in India and their implications.
Summary
Key Message
India is regarded as highest drug-resistant TB burden country accounting for estimated 27% of global cases. Challenge of addressing drug resistant TB is critical for India to achieve TB elimination targets of National TB program. Several heterogeneous factors have mediated the success of DR-TB management in India. In this article, we discuss, in brief, some of the major challenges and implications associated with reducing the growing DR-TB epidemic in India.

Citations

Citations to this article as recorded by  
  • Rifampicin-resistant Tuberculosis: A Global Health Dilemma
    Rahnuma Ahmad, Susmita Sinha, Kona Chowdhury, Mainul Haque
    Advances in Human Biology.2024; 14(2): 87.     CrossRef
  • Whole-genome sequencing of clinical isolates from tuberculosis patients in India: real-world data indicates a high proportion of pre-XDR cases
    Aparna Bhanushali, Sachin Atre, Preethi Nair, Geethanjali Anilkumar Thandaseery, Sanchi Shah, Sanjana Kuruwa, Amrutraj Zade, Chaitali Nikam, Mangala Gomare, Anirvan Chatterjee, Arryn Craney
    Microbiology Spectrum.2024;[Epub]     CrossRef
  • Double trouble: compounding effects of COVID-19 pandemic and antimicrobial resistance on drug resistant TB epidemiology in India
    Aliabbas A. Husain, Rajpal Singh Kashyap
    Frontiers in Public Health.2023;[Epub]     CrossRef
  • Snapshot of Mycobacterium tuberculosis Phylogenetics from an Indian State of Arunachal Pradesh Bordering China
    Shiv kumar Rashmi Mudliar, Umay Kulsum, Syed Beenish Rufai, Mika Umpo, Moi Nyori, Sarman Singh
    Genes.2022; 13(2): 263.     CrossRef
Epidemiol Health : Epidemiology and Health
© Korean Society of Epidemiology.